SCHEMBL1863293

SCHEMBL1863293

BrCc1ccc2sccc2c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.66
DYRK1A Q13627 1/20 0.42
PTPRC P08575 1/20 0.41
PTPN6 P29350 1/20 0.41
PTPN11 Q06124 1/20 0.41
PTPN22 Q9Y2R2 1/20 0.41
PDE10A Q9Y233 1/20 0.40
CTNNB1 P35222 1/20 0.40
WNT3A P56704 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
SLC6A4 P31645 4/20 0.38
SLC6A3 Q01959 4/20 0.38
SLC6A2 P23975 3/20 0.38
CA12 O43570 4/20 0.37
CA2 P00918 4/20 0.37
MRGPRX4 Q96LA9 1/20 0.36
OPRM1 P35372 1/20 0.36
OPRK1 P41145 1/20 0.36
KCNH2 Q12809 1/20 0.35
SLC5A2 P31639 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29469368 1.00 CYP2A6 (0.66) CYP2A6DYRK1APTPRCPTPN6PTPN11
SCHEMBL6399446 0.89 CYP2A6 (0.54) CYP2A6DYRK1APTPRCPTPN6PTPN11
SCHEMBL6399444 0.84 CYP2A6 (0.49) CYP2A6DYRK1APTPRCPTPN6PTPN11
SCHEMBL7465357 0.83 CYP2A6 (0.46) CYP2A6DYRK1APTPRCPTPN6PTPN11
SCHEMBL112311 0.79 CYP2A6 (1.00) CYP2A6DYRK1APTPRCPTPN6PTPN11
SCHEMBL202117 0.79 CYP2A6 (0.66) CYP2A6DYRK1APTPRCPTPN6PTPN11
SCHEMBL202744 0.79 CYP2A6 (0.66) CYP2A6DYRK1APTPRCPTPN6PTPN11
SCHEMBL6607954 0.79 CYP2A6 (0.66) CYP2A6DYRK1APTPRCPTPN6PTPN11
SCHEMBL1774025 0.79 CYP2A6 (0.66) CYP2A6DYRK1APTPRCPTPN6PTPN11
SCHEMBL8051994 0.79 CYP2A6 (0.66) CYP2A6DYRK1APTPRCPTPN6PTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11236062-B2 Method for producing 5-(bromomethyl)-1-benzothiophene FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP) 2022-02-01 US claimed
CN-109526218-B Preparation method of 5-bromomethyl-1-benzothiophene 富士胶片富山化学株式会社 2021-07-06 CN claimed
EP-3444243-B1 METHOD FOR PRODUCING 5-(BROMOMETHYL)-1-BENZOTHIOPHENE FUJIFILM TOYAMA CHEMICAL CO LTD (JP) 2020-09-02 EP claimed
US-20190119242-A1 METHOD FOR PRODUCING 5-(BROMOMETHYL)-1-BENZOTHIOPHENE FUJIFILM TOYAMA CHEMICAL CO., LTD. (JP) 2019-04-25 US claimed
CN-109526218-A The preparation method of 5- bromomethyl -1- benzothiophene 富士胶片富山化学株式会社 2019-03-26 CN claimed
EP-3444243-A1 METHOD FOR PRODUCING 5-(BROMOMETHYL)-1-BENZOTHIOPHENE FUJIFILM Toyama Chemical Co., Ltd. (JP) 2019-02-20 EP claimed
US-20240391940-A1 FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME GENEROS BIOPHARMA LTD. (GB) 2024-11-28 US disclosed
CN-118047780-A Quinazoline heterocyclic compound and anti-infection and anti-tumor application thereof 中国医学科学院药物研究所 2024-05-17 CN disclosed
EP-4234544-A1 FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME Generos Biopharma Ltd. (KY) 2023-08-30 EP disclosed
EP-4234544-A1 FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME Generos Biopharma Ltd. (KY) 2023-08-30 EP disclosed
CN-116457347-A Compound containing condensed rings, application thereof and composition containing compound 健艾仕生物医药有限公司 2023-07-18 CN disclosed
CN-114478482-A Compound containing condensed ring, application thereof and composition containing compound 健艾仕生物医药有限公司 2022-05-13 CN disclosed
WO-2022083731-A1 FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME 健艾仕生物医药有限公司 2022-04-28 WO disclosed
US-5776983-A ANTIDIABETIC AGENTS, OBESITY, GASTROINTESTINAL DISORDERS BRISTOL-MYERS SQUIBB COMPANY (US) 1998-07-07 US disclosed
WO-1997009311-A1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY F. HOFFMANN-LA ROCHE AG (CH) 1997-03-13 WO disclosed
EP-0659737-A2 Catecholamine surrogates useful as B3 agonists BRISTOL-MYERS SQUIBB COMPANY (US) 1995-06-28 EP disclosed
US-5194435-A Hypoglycemic Agent AMERICAN HOME PRODUCTS CORPORATION (US) 1993-03-16 US disclosed
US-5183825-A Antidiabetic agents AMERICAN HOME PRODUCTS CORPORATION (US) 1993-02-02 US disclosed
US-4611059-A THROMBOXANE A2(TXA2) SYNTHETASE INHIBITORS THE UPJOHN COMPANY (US) 1986-09-09 US disclosed
EP-0069521-A2 Pyridinyl and imidazolyl derivatives of benzofurans and benzothiophenes THE UPJOHN COMPANY (US) 1983-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11236062-B2 Method for producing 5-(bromomethyl)-1-benzothiophene BBOX1, BRD1, BRD7 CYP2A6 420/4885DYRK1A 2796/4885PTPRC 4027/4885
US-20240391940-A1 FUSED RING-CONTAINING COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME STAT5A, STAT5B, JAK2 CYP2A6 3288/4885DYRK1A 1243/4885PTPRC 161/4885
US-20190119242-A1 METHOD FOR PRODUCING 5-(BROMOMETHYL)-1-BENZOTHIOPHENE BBOX1, BRD1, BRD7 CYP2A6 420/4885DYRK1A 2796/4885PTPRC 4027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.